CMS Approved New Payment for icotec CMORE CT System
The Centers for Medicare & Medicaid Services has authorized a New Technology Add-On Payment for the spinal stabilization device.
Updated on Oct. 6, 2026 in Healthcare
Live Poll
Should government health programs provide extra payments to hospitals for using newly approved medical technologies?
The Centers for Medicare & Medicaid Services has approved a New Technology Add-On Payment for the icotec CMORE CT System. This decision allows hospitals to receive additional reimbursement when utilizing the system for traditional Medicare patients.
Why it matters
The program aims to offset the costs of adopting innovative medical technologies, ensuring that hospitals can offer advanced treatments to Medicare beneficiaries without incurring financial losses. This approval facilitates broader access to specialized spinal stabilization tools for patients in the United States.
The New Technology Add-On Payment approval represents a key policy milestone for the system, which received FDA clearance for treating spinal infections and secured Break-Through Device Designation.
The players
Centers for Medicare & Medicaid Services
This federal agency administers the Medicare program and oversees reimbursement policies for medical technologies in the United States.
icotec
Headquartered in Altstätten, Switzerland, with a U.S. base in Boston, the company develops non-metallic spinal implants.
The details
The CMORE CT System features polyaxial screws and rods made from Carbon/PEEK material specifically designed for posterior stabilization of the cervicothoracic spine. Hospitals using this technology for traditional Medicare patients are now eligible for additional financial support through the CMS reimbursement program.
Timeline
April 2025: The CMORE CT System received Break-Through Device Designation.
October 1, 2026: The New Technology Add-On Payment officially became effective.
October 6, 2026: The Centers for Medicare & Medicaid Services announced the approval.
Market Landscape
The designation underscores the ongoing trend of regulatory agencies prioritizing the integration of advanced biomaterials into clinical practice. This inclusion positions the product within a competitive reimbursement environment that rewards innovations targeting complex spinal stabilization needs.
Medicare patients requiring cervicothoracic spinal stabilization may find greater access to this specific technology as hospitals utilize the new reimbursement pathway. This change is designed to stabilize the financial viability of using high-tech implants for clinicians treating spinal infections.
The takeaway
The CMS approval provides a vital financial bridge for medical facilities to adopt high-performance spinal technologies. Hospitals and healthcare providers should review updated reimbursement coding to ensure they utilize the available incentives for qualified procedures.
Further reading
Learn more about the latest developments in Healthcare policy and medical device coverage.
More information
For additional technical specifications or clinical applications, visit the icotec product information website.
Live Poll
Should government health programs provide extra payments to hospitals for using newly approved medical technologies?
